Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 81, Issue 2, 2012, Pages 379-385

  Bautzová, Tereza ^a,b   Rabišková, Miloslava ^a   Béduneau, Arnaud ^b   Pellequer, Yann ^b   Lamprecht, Alf ^b,c  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

5 ASA; Chitosan; Colonic delivery; Experimental colitis; Pellets

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; CHITOSAN; DRUG METABOLITE; MYELOPEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; COLITIS; COLON; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG PELLET; DRUG RELEASE; DRUG SOLUBILITY; ILEUS; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOADHESION; NONHUMAN; PELLET EXTRUSION; PH; RAT; RECTUM HEMORRHAGE; SPHERONIZATION; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOPOLYMERS; CHITOSAN; COLITIS; COLON; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; HYDROGEN-ION CONCENTRATION; INFLAMMATION; MALE; MESALAMINE; PARTICLE SIZE; PEROXIDASE; RATS; RATS, WISTAR; SOLUBILITY;

EID: 84861636996     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.02.011     Document Type: Article

References (36)

1. C. Loddenkemper Diagnostic standards in the pathology of inflammatory bowel disease Dig. Dis. 27 2009 576 583
2. L.J. Egan, and W.J. Sandborn Drug therapy of inflammatory bowel disease Drugs Today (Barc) 34 1998 431 446
3. A. Kornbluth, and D.B. Sachar Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee Am. J. Gastroenterol. 105 2010 501 523
4. J.D. Lewis How safe are the safest IBD drugs? Gastroenterology 124 2003 1986 1988
5. D.R. Friend New oral delivery systems for treatment of inflammatory bowel disease Adv. Drug Deliv. Rev. 57 2005 247 265
6. J.D. Smart The basics and underlying mechanisms of mucoadhesion Adv. Drug Deliv. Rev. 57 2005 1556 1568
7. A.K. Singla, and M. Chawla Chitosan: some pharmaceutical and biological aspects - an update J. Pharm. Pharmacol. 53 2001 1047 1067
8. L. Illum Chitosan and its use as a pharmaceutical excipient Pharm. Res. 15 1998 1326 1331
9. V.K. Gupta, T.E. Beckert, and J.C. Price A novel pH- and time-based multi-unit potential colonic drug delivery system. I. Development Int. J. Pharm. 213 2001 83 91
10. G.P. Morris, P.L. Beck, M.S. Herridge, W.T. Depew, M.R. Szewczuk, and J.L. Wallace Hapten-induced model of chronic inflammation and ulceration in the rat colon Gastroenterology 96 1989 795 803
11. A. Lamprecht, N. Ubrich, H. Yamamoto, U. Schäfer, H. Takeuchi, P. Maincent, Y. Kawashima, and C.M. Lehr Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease J. Pharmacol. Exp. Ther. 299 2001 775 781
12. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles J. Control. Release 104 2005 337 346
13. J.E. Krawisz, P. Sharon, and W.F. Stenson Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models Gastroenterology 87 1984 1344 1350
14. K.V.R. Rao, and P. Buri A novel in situ method to test polymers and coated microparticles for bioadhesion Int. J. Pharm. 52 1989 265 270
15. B. Bystrowska, J. Nowak, and J. Brandys Validation of a LC method for the determination of 5-aminosalicylic acid and its metabolite in plasma and urine J. Pharm. Biomed. Anal. 22 2000 341 347
16. H. Steckel, and F. Mindermann-Nogly Production of chitosan pellets by extrusion/spheronization Eur. J. Pharm. Biopharm. 57 2004 107 114
17. A.G. Press, I.A. Hauptmann, L. Hauptmann, B. Fuchs, M. Fuchs, K. Ewe, and G. Ramadori Gastrointestinal pH profiles in patients with inflammatory bowel disease Aliment. Pharmacol. Ther. 12 1998 673 678
18. S.G. Nugent, D. Kumar, D.S. Rampton, and D.F. Evans Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs Gut 48 2001 571 577
19. D.L. French, and J.W. Mauger Evaluation of the physicochemical properties and dissolution characteristics of mesalamine: relevance to controlled intestinal drug delivery Pharm. Res. 10 1993 1285 1290
20. R.C. Schellekens, F.E. Stuurman, F.H. van der Weert, J.G. Kosterink, and H.W. Frijlink A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products Eur. J. Pharm. Sci. 30 2007 15 20
21. S.Y. Zhou, D. Fleisher, L.H. Pao, C. Li, B. Winward, and E.M. Zimmermann Intestinal metabolism and transport of 5-aminosalicylate Drug Metab. Dispos. 27 1999 479 485
22. F.J. Zijlstra, M.E. van Meeteren, I.M. Garrelds, and M.A. Meijssen Effect of pharmacologically induced smooth muscle activation on permeability in murine colitis Mediators Inflamm. 12 2003 21 27
23. M. Mori, Y. Shirai, Y. Uezono, T. Takahashi, Y. Nakamura, H. Makita, Y. Nakanishi, and Y. Imasato Influence of specific gravity and food on movement of granules in the gastrointestinal tract of rats Chem. Pharm. Bull. (Tokyo) 37 1989 738 741
24. H.T. Yao, C.K. Lii, R.H. Chou, J.H. Lin, H.T. Yang, and M.T. Chiang Effect of chitosan on hepatic drug-metabolizing enzymes and oxidative stress in rats fed low- and high-fat diets J. Agric. Food Chem. 58 2010 5187 5193
25. G. Frieri, R. Giacomelli, M. Pimpo, G. Palumbo, A. Passacantando, G. Pantaleoni, and R. Caprilli Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis Gut 47 2000 410 414
26. D.J. Dawson, R.W. Lobley, P.C. Burrows, J.A. Notman, M. Mahon, and R. Holmes Changes in jejunal permeability and passive permeation of sugars in intestinal biopsies in coeliac disease and Crohn's disease Clin. Sci. (Lond.) 74 1988 427 431
27. J.R. Turner Intestinal mucosal barrier function in health and disease Nat. Rev. Immunol. 9 2009 799 809
28. Y. Pellequer, V. Weissenborn, and A. Lamprecht Decreased drug penetration in inflamed tissue related to changed mucosal metabolism in experimental colitis J. Pharm. Sci. 96 2007 2145 2153
29. J. König, H. Glaeser, M. Keiser, K. Mandery, U. Klotz, and M.F. Fromm Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake Drug Metab. Dispos. 39 2011 1097 1102
30. K.A. Wojtal, J.J. Eloranta, P. Hruz, H. Gutmann, J. Drewe, A. Staumann, C. Beglinger, M. Fried, G.A. Kullak-Ublick, and S.R. Vavricka Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients Drug Metab. Dispos. 37 2009 1871 1877
31. D. Kietzmann, B. Moulari, A. Béduneau, Y. Pellequer, and A. Lamprecht Colonic delivery of carboxyfluorescein by pH-sensitive microspheres in experimental colitis Eur. J. Pharm. Biopharm. 76 2010 290 295
32. H.W. Xin, M. Schwab, and U. Klotz Transport studies with 5-aminosalicylate Eur. J. Clin. Pharmacol. 62 2006 871 875
33. S.B. Seo, H.J. Jeong, H.S. Chung, J.D. Lee, Y.O. You, T. Kajiuchi, and H.M. Kim Inhibitory effect of high molecular weight water-soluble chitosan on hypoxia-induced inflammatory cytokine production Biol. Pharm. Bull. 26 2003 717 721
34. A. Mirshafiey, A. Khodadadi, B.H. Rehm, M.R. Khorramizadeh, M.B. Eslami, A. Razavi, and F. Saadat Sodium alginate as a novel therapeutic option in experimental colitis Scand. J. Immunol. 61 2005 316 321
35. Y. Pellequer, Y. Meissner, N. Ubrich, and A. Lamprecht Epithelial heparin delivery via microspheres mitigates experimental colitis in mice J. Pharmacol. Exp. Therap. 321 2007 726 733
36. H. Tozaki, T. Odoriba, N. Okada, T. Fujita, A. Terabe, T. Suzuki, S. Okabe, S. Muranishi, and A. Yamamoto Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats J. Control. Release 82 2002 51 61